|
|
||||||||
1 From the Department of Anatomy II, University of Erlangen-Nürnberg, Erlangen, Germany; the 2 Laboratory of Mechanisms of Ocular Diseases, National Institutes of Health, National Eye Institute, Bethesda, Maryland; and the 3 Eye Hospital of the University of Munich, Munich, Germany.
| Abstract |
|---|
|
|
|---|
METHODS. A peptide antibody against a portion of the myosin-like domain of myocilin/TIGR was developed. Different ocular tissues from three human donors were investigated by one- and two-dimensional gel electrophoresis and Western blot analysis. Immunohistochemistry was performed on 25 human eyes enucleated because of posterior choroidal melanoma and on 7 normal human donor eyes.
RESULTS. By Western blot analysis, a band at approximately 57 kDa was visualized in cornea, trabecular meshwork, lamina cribrosa, optic nerve, retina, iris, ciliary body, and vitreous humor. By immunohistochemistry, immunoreactivity for myocilin/TIGR was observed in cells of the corneal epi- and endothelium and extracellularly in the corneal stroma and sclera. In the trabecular meshwork, cells of the uveal and corneoscleral meshwork were stained, as was the cribriform area directly adjacent to Schlemms canal. Positive staining was seen in cells of the ciliary epithelium, ciliary muscle, lens epithelium, and in stromal and smooth muscle cells of the iris. Throughout the entire vitreous body, fine filamentous material was positively labeled. In the retina, staining was seen along the outer surface of rods and cones, in neurons of the inner and outer nuclear layer, and in the axons of optic nerve ganglion cells. Optic nerve axons were stained in the prelaminar, laminar, and postlaminar parts of the nerve. In the region of the lamina cribrosa, astrocytes in the glial columns and cribriform plates were positively labeled.
CONCLUSIONS. Myocilin/TIGR is expressed in almost every ocular tissue. Depending on the respective tissue, it is observed extra- or intracellularly. The presence of myocilin/TIGR in optic nerve axons and lamina cribrosa astrocytes indicates that the trabecular meshwork might not be the only target of abnormal myocilin/TIGR in GLC1A-linked open-angle glaucoma.
| Introduction |
|---|
|
|
|---|
Myocilin/TIGR was originally isolated from cultured human TM cells that had been treated for a long time with dexamethasone18 19 20 21 and, independently, from normal human retina.22 In addition to TM and retina, mRNA for myocilin/TIGR is expressed in various intraocular and extraocular tissues, such as cornea, sclera, ciliary body, iris, heart, skeletal muscle, thymus, small intestine, colon, stomach, thyroid, and trachea.5 23 24 25 26 The normal role of myocilin/TIGR and the mechanisms by which mutations in this gene cause glaucoma are unknown. In addition, there is controversy about the exact cellular localization of myocilin/TIGR. Some authors reported that myocilin/TIGR is secreted by trabecular meshwork cells and hypothesized that myocilin/TIGR might act extracellularly on aqueous humor outflow.18 19 20 21 Others could not find evidence for such an extracellular localization of myocilin/TIGR, but observed myocilin/TIGR in the cytoplasm of trabecular meshwork cells27 28 or in association with the connecting cilium of the photoreceptors.22 In the present study, we developed a peptide antibody against myocilin/TIGR and used it as a tool to study the distribution and cellular localization of myocilin/TIGR in the human eye.
| Materials and Methods |
|---|
|
|
|---|
Ten pairs of normal human donor eyes (age range, 5184 years) obtained after autopsy and 25 eyes enucleated because of posterior choroidal melanoma (age range, 5481 years) were investigated. The melanoma eyes were obtained from the Eye Hospital of the University of Munich, Germany. After enucleation, normal donor eyes were cut equatorially behind the ora serrata. In eyes from three of the normal donors, cornea, trabecular meshwork, ciliary body, iris, retina, vitreous humor, lamina cribrosa, and optic nerve were isolated, deep-frozen, and processed for gel electrophoresis and Western blot analysis. In eyes from seven of the normal donors, the anterior segment was dissected in quadrants. From each quadrant, wedge-shaped specimens of 2 mm circumferential width, containing cornea, iris, ciliary body, sclera, and trabecular meshwork were cut and immersed in 4% paraformaldehyde for 24 hours. In addition, lens, retina, lamina cribrosa, and postlaminar optic nerve were cut free and immersed in the same fixative. Specimens from five pairs of the normal human autopsy eyes were placed in fixative within 4 hours after death; specimens from two pairs of the eyes were fixed within 10 hours after death. Melanoma eyes were processed within 10 minutes after surgical removal and fixed as a whole in 10% formalin.
Methods for securing human tissue were humane, included proper consent and approval, and complied with the Declaration of Helsinki.
Gel Electrophoresis and Western Blot Analysis
The sample was homogenized in 8 M urea with 2% Nonidet P-40
(American Bioanalytical, Natick, MA), centrifuged at 14000g for 10
minutes, and the supernatant was taken. Protein concentrations were
determined with the Coomassie protein assay (Pierce, Rockford, IL).
For one-dimensional (1D) gels, proteins (3 µg) were subjected to
SDS-PAGE on 12.5% gels using the Pharmacia PhastGel System (Pharmacia
LKB, Piscataway, NJ) and the gels were silver stained. Polypeptides
were transferred to nitrocellulose membranes according to the
manufacturers protocols and blocked for 1 hour. Membranes were
incubated with rabbit antibody to myocilin, and the blots were
subsequently incubated with CSPD chemiluminescence system (Tropix Inc.,
Bedford, MA). For two-dimensional (2D) gel electrophoresis and
immunoblotting, 3 µg of a trabecular meshwork homogenate was run on
isoelectric focusing gels and then on 12.5% sodium
dodecylsulfatepolyacrylamide gel electrophoresis (SDS-PAGE), exactly
as described previously.29
The immunoblotting was
performed using the Super Signal chemiluminescent method (Pierce),
using an Image Station 440 (NEN, Boston, MA) accoring to the
manufacturers instructions.
Immunohistochemistry
The localization of myocilin/TIGR was studied in paraffin sections
from both melanoma and normal donor eyes. The sections were placed on
slides covered with 0.1% poly-L-lysine and preincubated
for 45 minutes in dry milk solution.30
After
preincubation, the sections were incubated overnight at room
temperature with the myocilin/TIGR antibody diluted 1:501:100 in
phosphate-buffered saline (PBS). After overnight incubation, the
sections were washed in PBS, reacted for 1 hour with biotinylated
secondary antibodies against rabbit immunoglobulin (Vector
Laboratories, Burlingame, CA), washed again, and covered with
streptavidin-fluorescein isothiocyanate (FITC; Vector). Double-labeling
experiments were performed in specimens from eyes fixed in 4%
paraformaldehyde within 3 hours after enucleation. Sections were
incubated with myocilin/TIGR antibody in combination with mouse
anti-glial fibrillary acidic protein, mouse anti-neurofilament (1:25
and 1:5; Dako, Carpinteria, CA), and mouse anti-protein gene
product (PGP) 9.5 (1:100; UltraClon Ltd., Isle of Wight, UK).
Binding of rabbit antibodies was visualized using biotinylated
secondary antibodies and streptavidin-FITC. Mouse antisera were stained
with Cy 3conjugated anti-mouse IgG (Dianova, Hamburg, Germany).
After washing in PBS, the sections were mounted with fluorescent mounting medium (Dako) and viewed with a Leitz Aristoplan microscope (Ernst Leitz GmbH, Wetzlar, Germany). A Kodak T-max 400 film (Eastmann Kodak, Rochester, NY) was used for photography.
Control experiments were performed by incubating the myocilin/TIGR antibody with the specific peptide (1 µg/ml) or by using either PBS or preimmune serum from the same host species (rabbit, mouse) substituted for the primary antibody.
| Results |
|---|
|
|
|---|
|
|
Cornea
Intense staining for myocilin/TIGR was observed in cells of the
corneal epithelium (Fig. 3A
). The staining was most pronounced in the basal cells and was seen
throughout their entire cytoplasm.
|
Iris and Ciliary Body
In the iris, smooth muscle cells of the sphincter and dilator
muscle were positively stained for myocilin/TIGR, as were almost all
resident cells in the iris stroma (Figs. 4A
4B
). In addition, positive staining was seen in vascular endothelial
cells of iris vessels. In contrast to corneal epithelial and
endothelial cells, immunoreactivity for myocilin/TIGR of iris cells
appeared to be more intense in the periphery of the cytoplasm. In the
ciliary muscle, smooth muscle cells were labeled for myocilin/TIGR in
all parts of the muscle with equal intensity (Fig. 4C)
. Similar to
cells of the iris, positive staining of ciliary muscle cells was not
seen in all parts of the cytoplasm, but was more intense close to the
cell membrane (Fig. 4D)
. A similar pattern of staining was seen in the
vascular smooth muscle cells that surround ciliary body arteries and
arterioles (Fig. 4C)
. No staining for myocilin/TIGR was observed
extracellularly between individual ciliary muscle bundles or in cells
of the fibroblast sheaths that surround the muscle bundles.
|
|
|
|
|
|
Ciliary Nerves and Choroid
Similar to optic nerve axons, some larger myelinated axons in the
ciliary nerves were immunoreactive for myocilin/TIGR (Fig. 10) . Axonal staining for myocilin/TIGR showed colocalization with staining
for PGP 9.5 (Figs. 10C
10D)
and neurofilament (not shown). Staining
was also seen in cells of the perineurium and, weaker, in those of the
endoneurium. Smooth muscle cells of choroidal arteries and arterioles
were positively stained.
|
| Discussion |
|---|
|
|
|---|
The nature and function of myocilin/TIGR are largely unclear. Nguyen et al.21 reported that myocilin/TIGR is secreted by cultured trabecular meshwork cells into the surrounding culture medium, whereas others found only evidence for an intracellular localization of myocilin/TIGR in trabecular meshwork cells.27 28 Although our results provide for the first time clear evidence for an extracellular in situ localization of myocilin/TIGR in corneal stroma, sclera, and vitreous body, staining of the uveal and corneoscleral trabecular meshwork showed a distinct cellular staining of myocilin/TIGR. As for the myocilin/TIGR immunoreactivity in the cribriform or juxtacanalicular meshwork, it was not possible to clearly distinguish cellular from extracellular labeling, because of the technical limits of light microscopy. Clearly, studies using electron microscopy in conjunction with antibody labeling are necessary to define the exact localization of myocilin/TIGR in those parts of the trabecular meshwork that are most critical for aqueous humor outflow. Our results on myocilin/TIGR immunoreactivity in normal human trabecular meshwork in situ differ in some aspects from those previously reported by LütjenDrecoll et al.,27 who found only some cells in the inner parts of the meshwork positively stained for myocilin/TIGR and no immunoreactivity in the cribriform trabecular meshwork. This difference might be explained by the fact that a different antibody, generated against recombinant myocilin/TIGR, was used and that some epitopes critical for immunodetection by this antibody might have been lost during tissue processing.
Cellular staining for myocilin/TIGR was not confined to corneoscleral and uveal trabecular meshwork cells, but also was seen in other tissues of the anterior eye such as the corneal, ciliary, and lens epithelium, as well as the corneal endothelium, which all showed predominant labeling of their cytoplasm. A cytoplasmic localization of myocilin/TIGR might indicate a function of myocilin/TIGR different from those in tissues that express convincing extracellular labeling, such as the corneal stroma or the vitreous. Another likely possibility might be that these cells synthesize relatively large amounts of myocilin/TIGR and secrete it into the aqueous humor or in case of the corneal epithelium, into the inner mucous layer of the tear film. In support of the latter hypothesis appears to be the fact that myocilin/TIGR contains at its C terminus a relatively large olfactomedin domain.20 21 22 Olfactomedin is a component of the mucous layer of the frog olfactory epithelium.32 In other cell types, such as in cells of the iris stroma, and in vascular and ciliary smooth muscle cells, staining for myocilin/TIGR was predominantely associated with the peripheral cytoplasm close to the cell membrane. Direct membrane binding of myocilin/TIGR appears to be unlikely, because its protein sequence does not indicate the presence of domains that are regarded as characteristic for membrane-binding proteins. Still, myocilin/TIGR might associate with such proteins at the inner or outer surface of the cell membrane. Clearly, electron micoscopy is needed to clarify this issue.
In the retina, we found strong staining for myocilin/TIGR along the outer surface of rods and cones, but in contrast to others,22 no evidence for an association with the connecting cilium of the photoreceptors. Again, the exact ultrastructural localization of myocilin/TIGR remains to be clarified, but it is tempting to speculate that myocilin/TIGR might be part of the interphotoreceptor matrix. Other distinct retinal structures that showed positive labeling were the axons of the optic nerve ganglion cells. This labeling of optic nerve axons was not only seen in the optic nerve fiber layer, but also in its prelaminar, laminar and postlaminar parts. Although the function of myocilin/TIGR in optic nerve axons remains unclear, it appears to be a feature that is not unique to this kind of axons, because it also was observed in larger myelinated axons in the ciliary nerves.
In addition to optic nerve axons, astrocytes in the optic nerve head showed expression of myocilin/TIGR, which is in agreement with findings of others.33 34 This expression was confined to astrocytes in the glial columns and cribriform plates of the optic nerve, but was not seen in its postlaminar parts. For the human optic nerve, two subpopulations of astrocytes (1A and 1B) have been identified in the prelaminar and laminar regions.35 Type 1A astrocytes are present at the edges of the cribriform plates, whereas type 1B astrocytes are lining the cribriform plates and form the glial columns. Type 2 astrocytes are the predominant cell type in the myelinated postlaminar axon bundles. Based on this classification, myocilin/TIGR expression appears to be largely confined to 1B astrocytes. Different astrocyte populations are mainly distinguished by their different expression of various glial cell markers, whereas true differences in function remain largely unclear. In a recent study, we showed that myocilin/TIGR expression is induced upon mechanical stretch.36 Clearly, the lamina cribrosa is the part of the optic nerve that is most prone to mechanical influences that are caused by changes in IOP or eye movements.37 The function of myocilin/TIGR expressed by lamina cribrosa astrocytes might be associated with such factors.
Recently, mutations in the gene for myocilin/TIGR, which lie within the interval on chromosome 1 that was originally associated with juvenile open angle-glaucoma (GLC1A), have been identified in patients with autosomal-dominant juvenile open-angle glaucoma, as well as in some patients with adult-onset POAG.1 5 6 9 13 Because these patients express, depending on the site of the respective mutation, a relatively high IOP that requires early surgical treatment14 15 17 and because myocilin/TIGR has originally been isolated from cultured human trabecular meshwork cells,20 21 it has been generally assumed that the function of the trabecular meshwork for aqueous humor outflow is primarily affected by mutations in the coding sequences of myocilin/TIGR. Our findings of myocilin/TIGR expression in optic nerve axons and astrocytes indicate that abnormal myocilin/TIGR might also primarily interfere with function and survival of optic nerve axons in the lamina cribrosa. The trabecular meshwork might not be the only target of abnormal myocilin/TIGR in GLC1A-linked glaucoma.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication May 7, 1999; revised October 13, 1999; accepted October 26, 1999.
Commercial relationships policy: N.
Presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May, 1999.
Corresponding author: Ernst R. Tamm, Department of Anatomy II, University of Erlangen-Nürnberg, Universitätsstr. 19, D-91054 Erlangen, Germany. ertamm{at}anatomie.uni-erlangen.de
| References |
|---|
|
|
|---|
B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork Invest Ophthalmol Vis Sci 39,517-525This article has been cited by other articles:
![]() |
J.-D. Aroca-Aguilar, F. Martinez-Redondo, F. Sanchez-Sanchez, M. Coca-Prados, and J. Escribano Functional Role of Proteolytic Processing of Recombinant Myocilin in Self-Aggregation Invest. Ophthalmol. Vis. Sci., January 1, 2010; 51(1): 72 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Pfeffer, C. A. DeWitt, M. Salvador-Silva, M. E. Cavet, F. J. Lopez, and K. W. Ward Reduced Myocilin Expression in Cultured Monkey Trabecular Meshwork Cells Induced by a Selective Glucocorticoid Receptor Agonist: Comparison with Steroids Invest. Ophthalmol. Vis. Sci., January 1, 2010; 51(1): 437 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Koga, X. Shen, J.-S. Park, Y. Qiu, B.-C. Park, R. Shyam, and B. Y.J.T. Yue Differential Effects of Myocilin and Optineurin, Two Glaucoma Genes, on Neurite Outgrowth Am. J. Pathol., January 1, 2010; 176(1): 343 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-Y. Jia, B. Gong, C.-P. Pang, Y. Huang, D. S.-C. Lam, N. Wang, and G. H.-F. Yam Correction of the Disease Phenotype of Myocilin-Causing Glaucoma by a Natural Osmolyte Invest. Ophthalmol. Vis. Sci., August 1, 2009; 50(8): 3743 - 3749. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-S. Kwon, H.-S. Lee, Y. Ji, J. S. Rubin, and S. I. Tomarev Myocilin Is a Modulator of Wnt Signaling Mol. Cell. Biol., April 15, 2009; 29(8): 2139 - 2154. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Hoffman, K. M. Perkumas, L. M. Highstrom, and W. D. Stamer Regulation of Myocilin-Associated Exosome Release from Human Trabecular Meshwork Cells Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1313 - 1318. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Russell, J. Z. Gasiorowski, P. F. Nealy, and C. J. Murphy Response of Human Trabecular Meshwork Cells to Topographic Cues on the Nanoscale Level Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 629 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sanchez-Sanchez, F. Martinez-Redondo, J. D. Aroca-Aguilar, M. Coca-Prados, and J. Escribano Characterization of the Intracellular Proteolytic Cleavage of Myocilin and Identification of Calpain II as a Myocilin-processing Protease J. Biol. Chem., September 21, 2007; 282(38): 27810 - 27824. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H.-F. Yam, K. Gaplovska-Kysela, C. Zuber, and J. Roth Sodium 4-Phenylbutyrate Acts as a Chemical Chaperone on Misfolded Myocilin to Rescue Cells from Endoplasmic Reticulum Stress and Apoptosis Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1683 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H.-F. Yam, K. Gaplovska-Kysela, C. Zuber, and J. Roth Aggregated Myocilin Induces Russell Bodies and Causes Apoptosis: Implications for the Pathogenesis of Myocilin-Caused Primary Open-Angle Glaucoma Am. J. Pathol., January 1, 2007; 170(1): 100 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Gould, M. Reedy, L. A. Wilson, R. S. Smith, R. L. Johnson, and S. W. M. John Mutant Myocilin Nonsecretion In Vivo Is Not Sufficient To Cause Glaucoma Mol. Cell. Biol., November 15, 2006; 26(22): 8427 - 8436. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Malyukova, H.-S. Lee, R. N. Fariss, and S. I. Tomarev Mutated Mouse and Human Myocilins Have Similar Properties and Do Not Block General Secretory Pathway Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 206 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Fautsch, C. K. Bahler, A. M. Vrabel, K. G. Howell, N. Loewen, W. L. Teo, E. M. Poeschla, and D. H. Johnson Perfusion of His-Tagged Eukaryotic Myocilin Increases Outflow Resistance in Human Anterior Segments in the Presence of Aqueous Humor Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 213 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Aroca-Aguilar, F. Sanchez-Sanchez, S. Ghosh, M. Coca-Prados, and J. Escribano Myocilin Mutations Causing Glaucoma Inhibit the Intracellular Endoproteolytic Cleavage of Myocilin between Amino Acids Arg226 and Ile227 J. Biol. Chem., June 3, 2005; 280(22): 21043 - 21051. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Aung, V. H. K. Yong, P. T. K. Chew, S. K. L. Seah, G. Gazzard, P. J. Foster, and E. N. Vithana Molecular Analysis of the Myocilin Gene in Chinese Subjects with Chronic Primary-Angle Closure Glaucoma Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1303 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zillig, A. Wurm, F. J. Grehn, P. Russell, and E. R. Tamm Overexpression and Properties of Wild-Type and Tyr437His Mutated Myocilin in the Eyes of Transgenic Mice Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 223 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhao, K. E. Ramsey, D. A. Stephan, and P. Russell Gene and Protein Expression Changes in Human Trabecular Meshwork Cells Treated with Transforming Growth Factor-{beta} Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 4023 - 4034. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Gould, L. Miceli-Libby, O. V. Savinova, M. Torrado, S. I. Tomarev, R. S. Smith, and S. W. M. John Genetically Increasing Myoc Expression Supports a Necessary Pathologic Role of Abnormal Proteins in Glaucoma Mol. Cell. Biol., October 15, 2004; 24(20): 9019 - 9025. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gobeil, M.-A. Rodrigue, S. Moisan, T. D. Nguyen, J. R. Polansky, J. Morissette, and V. Raymond Intracellular Sequestration of Hetero-oligomers Formed by Wild-Type and Glaucoma-Causing Myocilin Mutants Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3560 - 3567. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Goldwich, C. R. Ethier, D. W.-H. Chan, and E. R. Tamm Perfusion with the Olfactomedin Domain of Myocilin Does Not Affect Outflow Facility Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 1953 - 1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sohn, W. Hur, M. K. Joe, J.-H. Kim, Z.-W. Lee, K.-S. Ha, and C. Kee Expression of Wild-Type and Truncated Myocilins in Trabecular Meshwork Cells: Their Subcellular Localizations and Cytotoxicities Invest. Ophthalmol. Vis. Sci., December 1, 2002; 43(12): 3680 - 3685. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Filla, X. Liu, T. D. Nguyen, J. R. Polansky, C. R. Brandt, P. L. Kaufman, and D. M. Peters In Vitro Localization of TIGR/MYOC in Trabecular Meshwork Extracellular Matrix and Binding to Fibronectin Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 151 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wentz-Hunter, J. Ueda, and B. Y. J. T. Yue Protein Interactions with Myocilin Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 176 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ahmed, M. Torrado, E. Johnson, J. Morrison, and S. I. Tomarev Changes in mRNA Levels of the Myoc/Tigr Gene in the Rat Eye after Experimental Elevation of Intraocular Pressure or Optic Nerve Transection Invest. Ophthalmol. Vis. Sci., December 1, 2001; 42(13): 3165 - 3172. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Kim, O. V. Savinova, M. V. Reedy, J. Martin, Y. Lun, L. Gan, R. S. Smith, S. I. Tomarev, S. W. M. John, and R. L. Johnson Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function Mol. Cell. Biol., November 15, 2001; 21(22): 7707 - 7713. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Fautsch and D. H. Johnson Characterization of Myocilin-Myocilin Interactions Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2324 - 2331. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lindsey, D. D. Gaton, T. Sagara, J. R. Polansky, P. L. Kaufman, and R. N. Weinreb Reduced TIGR/Myocilin Protein in the Monkey Ciliary Muscle after Topical Prostaglandin F2{{alpha}} Treatment Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1781 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Russell, E. R. Tamm, F. J. Grehn, G. Picht, and M. Johnson The Presence and Properties of Myocilin in the Aqueous Humor Invest. Ophthalmol. Vis. Sci., April 1, 2001; 42(5): 983 - 986. [Abstract] [Full Text] |
||||
![]() |
N. Jacobson, M. Andrews, A. R. Shepard, D. Nishimura, C. Searby, J. H. Fingert, G. Hageman, R. Mullins, B. L. Davidson, Y. H. Kwon, et al. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor Hum. Mol. Genet., January 1, 2001; 10(2): 117 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Fautsch, C. K. Bahler, D. J. Jewison, and D. H. Johnson Recombinant TIGR/MYOC Increases Outflow Resistance in the Human Anterior Segment Invest. Ophthalmol. Vis. Sci., December 1, 2000; 41(13): 4163 - 4168. [Abstract] [Full Text] |
||||
![]() |
J. Ueda, K. K. Wentz-Hunter, E. L. Cheng, T. Fukuchi, H. Abe, and B. Y.J.T. Yue Ultrastructural Localization of Myocilin in Human Trabecular Meshwork Cells and Tissues J. Histochem. Cytochem., October 1, 2000; 48(10): 1321 - 1330. [Abstract] [Full Text] |
||||
![]() |
R. E. Swiderski, J. L. Ross, J. H. Fingert, A. F. Clark, W. L. M. Alward, E. M. Stone, and V. C. Sheffield Localization of MYOC Transcripts in Human Eye and Optic Nerve by In Situ Hybridization Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3420 - 3428. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |